Valuation: Nutriband Inc.

Market Cap 37.81M 33.04M 30.49M 28.1M 52.96M 3.64B 54.14M 364M 143M 1.78B 142M 139M 6.14B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 33.48M 29.25M 27M 24.88M 46.9M 3.22B 47.94M 323M 127M 1.58B 126M 123M 5.44B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
43.12%
Yield 2025 *
-
Yield 2026 -
1 day-0.64%
1 week+5.07%
Current month-2.51%
1 month+7.24%
3 months-27.67%
6 months-28.67%
Current year-31.50%
1 week 2.93
Extreme 2.93
3.15
1 month 2.91
Extreme 2.91
3.44
Current year 2.9
Extreme 2.9
4.98
1 year 2.9
Extreme 2.9
9.21
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
12.86
10 years 0.86
Extreme 0.8571
43.54
Manager TitleAgeSince
Chief Executive Officer 35 01/01/2016
Chief Executive Officer 52 -
Director of Finance/CFO 77 02/09/2020
Director TitleAgeSince
Chairman 52 21/01/2022
Director/Board Member 48 01/07/2018
Director/Board Member 38 01/07/2018
Date Insider Type Main position Quantity % Market Cap.
31/01/25 Other

Founder

126,833 1.1420%
31/01/25 Option

Chief Financial Officer

212,837 1.9164%
20/03/24 Free

Founder

75,000 0.9575%
Change 5-day change 1-year change 3-year change Capi.($)
-0.64%+5.07%-61.65%-20.87% 37.81M
+1.87%+7.19%-18.59%-6.15% 175B
-0.43%-0.80%-7.15%-3.39% 106B
-0.03%+1.47%+5.13%+60.41% 59.91B
+0.66%+0.96%+37.64%+54.22% 51.95B
-1.10%+4.10%-11.56%-37.95% 43.58B
-3.21%-3.05% - - 33.65B
-1.71%+2.25%-8.63%-42.64% 29.58B
-1.16%+1.28%+69.87%-7.10% 25.31B
-1.49%+0.85%-3.43%-4.22% 21.23B
Average -0.72%+1.93%+0.18%-0.85% 54.71B
Weighted average by Cap. +0.09%+2.75%-1.61%+3.53%

Financials

2025 2026
Net sales 2.14M 1.87M 1.73M 1.59M 3M 206M 3.06M 20.62M 8.11M 101M 8.04M 7.86M 347M 2.04M 1.78M 1.64M 1.51M 2.85M 196M 2.92M 19.63M 7.72M 96.06M 7.65M 7.48M 331M
Net income -10.48M -9.16M -8.45M -7.79M -14.69M -1.01B -15.01M -101M -39.74M -494M -39.37M -38.5M -1.7B -8.23M -7.19M -6.64M -6.12M -11.53M -793M -11.79M -79.32M -31.2M -388M -30.91M -30.23M -1.34B
Net Debt -4.13M -3.61M -3.33M -3.07M -5.78M -397M -5.91M -39.76M -15.64M -195M -15.49M -15.15M -670M -4.33M -3.78M -3.49M -3.22M -6.07M -417M -6.2M -41.73M -16.41M -204M -16.26M -15.9M -703M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
17/07/26 $3.110 -0.64% 13,447
16/07/26 $3.130 +2.62% 23,682
15/07/26 $3.050 +2.35% 29,175
14/07/26 $2.980 +1.36% 9,253
13/07/26 $2.940 -0.68% 6,923
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.110USD
Average target price
15.00USD
Spread / Average Target
+382.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock